Karyopharm Therapeutics Aktie News

Aktie
WKN:  A40YLC ISIN:  US48576U2050 US-Symbol:  KPTI Branche:  Biotechnologie Land:  USA
6,59 $
-0,05 $
-0,75%
5,5712 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
3,52 Mio. €
Streubesitz
60,73%
KGV
-0,61
Index-Zuordnung
-

Karyopharm Therapeutics News

12.01.26 - PR Newswire
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 PR Newswire
02.01.26 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.12.25 - PR Newswire
Karyopharm to Participate in Baird's Biotech Discovery Series
Karyopharm to Participate in Baird's Biotech Discovery Series PR Newswire
01.12.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.12.25 - PR Newswire
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference PR Newswire
03.11.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.11.25 - PR Newswire
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress PR Newswire
27.10.25 - PR Newswire
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 PR Newswire
08.10.25 - PR Newswire
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 ...
01.10.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
10.09.25 - PR Newswire
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis PR Newswire
02.09.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
11.08.25 - PR Newswire
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress PR Newswire
05.08.25 - PR Newswire
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 PR Newswire
01.08.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
01.07.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
03.06.25 - PR Newswire
Karyopharm to Present at the Jefferies Global Healthcare Conference
Karyopharm to Present at the Jefferies Global Healthcare Conference PR Newswire
02.06.25 - PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
19.05.25 - PR Newswire
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference PR Newswire
14.05.25 - PR Newswire
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »